PD-1 (anchoring) / IL-2Rβγ (cis-activation)

Class

PD-1-anchored IL-2 mutein fusion protein (immunocytokine)

Pathway

PD-1 blockade combined with PD-1-restricted (cis) IL-2 receptor activation on tumor-infiltrating T cells

PD-1 is a receptor found on the surface of T cells, cells of the immune system, after they have been activated by their target. When PD-1 engages its partners, PD-L1 or PD-L2, it dampens further T cell activity — a control mechanism that also allows tumors to suppress the T cells that would attack them. Interleukin-2 (IL-2) is a signaling protein with the opposite effect: it drives T cell proliferation and enhances their ability to kill target cells. Ordinary IL-2 acts broadly, on any cell bearing an IL-2 receptor, including regulatory T cells (Tregs), which suppress rather than support anti-tumor immunity, and vascular tissue, where it can cause fluid leakage. This mechanism combines both ideas in a single fusion protein. It carries a PD-1-binding portion that blocks the checkpoint, releasing the brake on T cell activity, and an engineered ("mutein") version of IL-2 designed to signal preferentially on the same cell to which the fusion protein has attached, a process called cis-activation. Because PD-1 is enriched on T cells that have already recognized tumor antigen, this design aims to concentrate IL-2 stimulation on tumor-relevant T cells rather than broadly across the body. The approach is relevant across solid tumors where checkpoint blockade alone produces incomplete T cell expansion.